Skip to main content
Advertising

Originally published Wednesday, May 1, 2013 at 2:15 PM

  • Share:
             
  • Comments (0)
  • Print

News Summary: Generic rivals hurt Merck results

BAD NEWS: First-quarter sales and net income for Merck & Co. both plunged - 9 percent and 8 percent, respectively - as the world's third-largest drugmaker got slammed by generic competition to multiple drugs. It cut its earnings forecast, sending shares down 3 percent in unusually heavy trading.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

BAD NEWS: First-quarter sales and net income for Merck & Co. both plunged - 9 percent and 8 percent, respectively - as the world's third-largest drugmaker got slammed by generic competition to multiple drugs. It cut its earnings forecast, sending shares down 3 percent in unusually heavy trading.

THE FORECAST: Merck said it expects better results in the second half of the year. It's now expecting 2013 earnings per share of $3.45 to $3.55, 15 cents below its February forecast.

ON DECK: Merck has five drugs under review by regulators, including a promising insomnia medicine called suvorexant.

News where, when and how you want it

Email Icon

Relive the magic

Relive the magic

Shop for unique souvenirs highlighting great sports moments in Seattle history.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►